0001493152-23-006348.txt : 20230301 0001493152-23-006348.hdr.sgml : 20230301 20230301080527 ACCESSION NUMBER: 0001493152-23-006348 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230301 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230301 DATE AS OF CHANGE: 20230301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ProPhase Labs, Inc. CENTRAL INDEX KEY: 0000868278 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 232577138 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21617 FILM NUMBER: 23689857 BUSINESS ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 BUSINESS PHONE: (215) 345-0919 MAIL ADDRESS: STREET 1: 711 STEWART AVE, SUITE 200 STREET 2: GARDEN CITY CITY: NEW YORK STATE: NY ZIP: 11530 FORMER COMPANY: FORMER CONFORMED NAME: QUIGLEY CORP DATE OF NAME CHANGE: 19930328 8-K 1 form8-k.htm
0000868278 false 0000868278 2023-03-01 2023-03-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 1, 2023

 

PROPHASE LABS, INC.

(Exact name of Company as specified in its charter)

 

Delaware   000-21617   23-2577138

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

711 Stewart Avenue, Suite 200

Garden City, New York

   11530
(Address of principal executive offices)   (Zip Code)

 

Company’s telephone number, including area code: (215) 345-0919

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Exchange Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, par value $0.0005   PRPH   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

On March 1, 2023, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its collaboration with mProbe, Inc. and Mayo Clinic for the continuing development of the BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test and outlining its roadmap for commercialization. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information included in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein. The furnishing of the information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is not intended to, and does not, constitute a determination or admission by the Company that such information is material, or that investors should consider such information before making an investment or voting decision with respect to the Company.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

No.   Description
     
99.1   Press Release dated March 1, 2023
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ProPhase Labs, Inc.
   
  By: /s/ Robert Morse
    Robert Morse
    Controller (principal financial officer and principal accounting officer)

 

Date: March 1, 2023

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

ProPhase Labs Announces Collaboration with mProbe, Inc. and Mayo Clinic for the Continuing Development of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test

 

Company Outlines BE-Smart Test Roadmap for Commercialization in the U.S.

 

Company in Early Stages of Exploring Development for Commercialization in Other Countries

 

Garden City, NY, March 1, 2023 (GLOBE NEWSWIRE) — ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced a collaboration with mProbe, Inc. (“mProbe”), a precision health and medicine company utilizing clinical proteomics in the oncology space, and Dr. Christopher Hartley of Mayo Clinic for the continued development of its BE-Smart Esophageal Pre-Cancer Diagnostic Screening test.

 

mProbe plans to continue testing specimens provided by the Mayo Clinic in the first quarter of 2023. ProPhase Labs intends to pursue initial commercialization of the BE-Smart test as a laboratory developed test (LDT) and for research use only (RUO) in the third quarter of 2023, once 500 specimens have been tested by mProbe. Clinical validation of the BE-Smart test for mass spectrometry for non-insurance payers is estimated to commence in the third quarter of 2023. Full commercialization backed by insurance is expected to commence by mid-2024.

 

The BE-Smart test has been previously tested on over 200 human samples to date by mProbe in conjunction with Dr. Christopher Hartley and Mayo Clinic and has shown an area under curve of greater than 99% in distinguishing highly impactful histologic classifications.[1] The initial protein-histologic correlations have also been redemonstrated in an unrelated RNA sequencing data set. Additional pilot findings include 100% accuracy in predicting invasive carcinoma in biopsy specimens that were otherwise uninformative about invasion histologically. The assay’s performance in this regard was confirmed with subsequent resection or synchronous endoscopic ultrasound findings.

 

Ted Karkus, ProPhase Lab’s Chief Executive Officer, commented, “We are excited to announce this continued collaboration and outline our development and early commercialization strategy for the BE-Smart diagnostic test, which we believe could become an important and potentially lifesaving test. Approximately 83% of esophageal adenocarcinoma (EAC) patients die of this terrible disease within six months to five years of diagnosis.[2] If diagnosed potentially years earlier with our diagnostic test, an ablation procedure may destroy the pre-cancerous cells before developing into cancer. With partners like mProbe and Dr. Hartley of the Mayo Clinic, we are optimistic that we can meet our commercialization goals for this potentially life-saving test. We are also in preliminary discussions to license, develop and ultimately commercialize our BE-Smart test in other countries.”

 

Mr. Karkus continued, “ProPhase is ahead of schedule in hiring an expert consultant to initiate its evaluation and cost benefit analysis toward obtaining CPT codes. The Company expects to pursue reimbursement rates in the range of $1,000 to $2,000 per test, based on CPT codes of similarly complex tests[3] and with gross profit margins approaching 75% as volumes grow. Our initial target market is 2 million endoscopies performed annually on patients with Barrett’s esophagus, which equates to a $2 billion to $4 billion potential market just in the U.S. mProbe and Mayo Clinic aim to study 1,000 specimens in total by the end of 2023, which will enable ProPhase to pursue full commercialization as an LDT.”

 

 
 

 

 

ProPhase Labs has also begun to establish various touchpoints with key opinion leaders (KOLs) and will continue to do so throughout 2023 to increase awareness of the Company’s ongoing development of the BE-Smart test and lay the groundwork for its eventual adoption once fully validated and commercially available.

 

About the BE-Smart Test

 

The BE-Smart Esophageal Pre-Cancer Diagnostic Screening test is aimed at early detection of esophageal cancer. It has already been tested by an independent test lab, mProbe, Inc. on over 200 human samples and has shown an area under curve of greater than 99% in distinguishing highly impactful histologic classifications.[1] ProPhase Labs plans to pursue initial commercialization of the BE-Smart test as an LDT and RUO. The goal of widespread adoption of the BE-Smart diagnostic test would allow health care providers to initiate potentially lifesaving early treatment processes such as an ablation procedure to remove the precancerous cells and could also significantly reduce unnecessary endoscopies.

 

About ProPhase Labs

 

ProPhase Labs, Inc. (Nasdaq: PRPH) (“ProPhase”) is a growth oriented and diversified diagnostics, genomics and biotech company that seeks to leverage its CLIA lab services to provide whole genome sequencing and research direct to consumers and build a genomics database to be used for further research. The Company provides traditional CLIA molecular laboratory services, including COVID-19 testing. The Company also operates Pharmaloz, a rapidly growing contract manufacturing subsidiary, and offers the TK Supplements line of dietary supplements, which are distributed in food, drug, and mass stores throughout the country.

 

ProPhase Diagnostics, Inc., a wholly owned subsidiary of ProPhase, offers a broad array of clinical diagnostic and testing services at its CLIA certified laboratories including polymerase chain reaction (PCR) testing for SARS-CoV-2 (COVID-19) and Influenza A and Influenza B. Critical to COVID-19 testing, ProPhase Diagnostics provides fast turnaround times for results. ProPhase Diagnostics also offers best-in-class rapid antigen tests to broaden its COVID-19 testing beyond RT-PCR testing. The Company has announced plans for the expansion of the lab to include traditional clinical testing and genomics sequencing.

 

Nebula Genomics, a rapidly growing and wholly owned subsidiary of ProPhase, focuses on genomics sequencing and testing technologies, a comprehensive method for analyzing entire genomes, including the genes and chromosomes in DNA. The data obtained from genomic sequencing may help to identify inherited disorders and tendencies, help predict disease risk, help identify expected drug response, and characterize genetic mutations, including those that drive cancer progression. The Company currently offers Nebula Genomics whole genome sequencing products direct-to-consumer online, with plans to sell in food, drug and mass (FDM) stores and to provide testing for universities conducting genomic research.

 

ProPhase BioPharma, Inc. (PBIO), a wholly owned subsidiary of ProPhase, was formed for the licensing, development and commercialization of novel drugs and compounds. Licensed compounds currently include Equivir (OTC/dietary supplement) and Equivir G (Rx), two broad based anti-virals, and Linebacker LB-1 and LB-2, two small molecule PIM kinase inhibitors. The company is collaborating with the Dana Farber Cancer Institute to develop LB-1 as a cancer co- therapy. The Company also owns the exclusive rights to the BE-Smart Esophageal Pre-Cancer Diagnostic Screening test and related IP assets. The BE-Smart test remains under validation as a LDT. The test is focused on the early detection of esophageal cancer and is intended to provide health care providers and patients with data to help determine treatment options.

 

 
 

 

 

ProPhase Labs has decades of experience researching, developing, manufacturing, distributing, marketing, and selling OTC consumer healthcare products and dietary supplements under the TK Supplements® brand and Pharmaloz contract manufacturing subsidiary.

 

ProPhase actively pursues strategic investments and acquisition opportunities for other companies, technologies, and products.

 

For more information, visit www.ProPhaseLabs.com.

 

References

1.Abdo, J., Wichman, C. S., Dietz, N. E., Ciborowski, P., Fleegel, J., Mittal, S. K., & Agrawal, D. K. (2018). Discovery of Novel and Clinically Relevant Markers in Formalin-Fixed Paraffin-Embedded Esophageal Cancer Specimen. Frontiers in Oncology, 8. https://doi.org/10.3389/fonc.2018.00157
   
2.https://jgo.amegroups.com/article/view/53833/html
   
3.https://bassett.testcatalog.org/catalogs/191/files/6843

 

Forward Looking Statements

 

Except for the historical information contained herein, this document contains forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our strategy, plans, objectives and initiatives, including our anticipated timeline for developing and commercializing the BE-Smart diagnostic test, our estimates regarding the target market for esophageal cancer, and the reimbursement rates for the BE-Smart diagnostic test we plan to pursue, as well as our plans to expand our New York lab to include traditional clinical testing and genomic sequencing, to sell our whole genome sequencing products in food, drug and mass (FDM) stores and to provide testing for universities conducting genomic research, and our ability to develop and commercialize LB-1 as a cancer co-therapy. Management believes that these forward-looking statements are reasonable as and when made.

 

However, such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those projected in the forward-looking statements. These risks and uncertainties include but are not limited to our ability to obtain and maintain necessary regulatory approvals, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment, and the risk factors listed from time to time in our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and any other SEC filings. The Company undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers are cautioned that forward-looking statements are not guarantees of future performance and are cautioned not to place undue reliance on any forward-looking statements.

 

 
 

 

 

Media Relations and Institutional Investor Contact:

 

ProPhase Labs, Inc.

267-880-1111

investorrelations@prophaselabs.com

 

Retail Investor Relations Contact:

 

Renmark Financial Communications

John Boidman

514-939-3989

Jboidman@renmarkfinancial.com

 

Source: ProPhase Labs, Inc.

 

###

 

 

 

 GRAPHIC 3 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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end EX-101.SCH 4 prph-20230301.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 prph-20230301_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 prph-20230301_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Mar. 01, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 01, 2023
Entity File Number 000-21617
Entity Registrant Name PROPHASE LABS, INC.
Entity Central Index Key 0000868278
Entity Tax Identification Number 23-2577138
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 711 Stewart Avenue
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Garden City
Entity Address, State or Province NY
Entity Address, Postal Zip Code 11530
City Area Code (215)
Local Phone Number 345-0919
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0005
Trading Symbol PRPH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000868278 2023-03-01 2023-03-01 iso4217:USD shares iso4217:USD shares 0000868278 false 8-K 2023-03-01 PROPHASE LABS, INC. DE 000-21617 23-2577138 711 Stewart Avenue Suite 200 Garden City NY 11530 (215) 345-0919 false false false false Common Stock, par value $0.0005 PRPH NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://prophaselabs.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm prph-20230301.xsd prph-20230301_lab.xml prph-20230301_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "prph-20230301_lab.xml" ] }, "presentationLink": { "local": [ "prph-20230301_pre.xml" ] }, "schema": { "local": [ "prph-20230301.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PRPH", "nsuri": "http://prophaselabs.com/20230301", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-03-01to2023-03-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://prophaselabs.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-03-01to2023-03-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://prophaselabs.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-006348-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-006348-xbrl.zip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